Overview

DOT HeartMate 3 Study

Status:
Not yet recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
A prospective, single-center, randomized controlled trial of the feasibility and safety of apixaban in HeartMate 3 patients.
Phase:
N/A
Details
Lead Sponsor:
Institute for Clinical and Experimental Medicine
Treatments:
Apixaban